CLEC3A: A Potential Drug Target and Biomarker (G10143)

Target Name: CLEC3A

NCBI ID: G10143

CLEC3A

Other Name(s): C-type lectin domain family 3 member A precursor | C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 1 (cartilage-derived) | CLC3A_HUMAN | C-type lectin superfamily member 1 | C-type lectin domain family 3 member A | Cartilage-derived C-type lectin | CLECSF1

CLEC3A: A Potential Drug Target and Biomarker

CLEC3A, or clec3-alpha, is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. Its primary function is to regulate the levels of sugar in the bloodstream. It is a key regulator of the insulin-sensitivity pathway, which is crucial for the proper functioning of the body's cells.

Recent studies have identified clec3-alpha as a potential drug target in the treatment of type 2 diabetes. Insulin resistance, which is a common complication in this disease, is associated with an increased risk of cardiovascular events. The insulin-sensitivity pathway is disrupted in individuals with type 2 diabetes, leading to an increase in the risk of complications.

Clec3-alpha has been shown to play a crucial role in the regulation of insulin sensitivity. It is a key regulator of the PI3K/AKT signaling pathway, which is responsible for the signaling of the insulin-sensitive pathway. This pathway is important for the proper functioning of the body's cells, including the brain.

Research has also shown that clec3-alpha is involved in the regulation of inflammation. Chronic inflammation is a major risk factor for the development and progression of type 2 diabetes. The inflammation that occurs in individuals with type 2 diabetes can contribute to the destruction of the insulin-sensitive cells in the body, leading to an increase in the risk of complications.

Clec3-alpha has also been shown to play a role in the regulation of energy metabolism. It is a regulator of the mitochondrial function and has been shown to play a role in the regulation of the citric acid cycle, which is important for the production of energy.

In conclusion, clec3-alpha is a protein that has been identified as a potential drug target in the treatment of type 2 diabetes. Its role in the regulation of insulin sensitivity, inflammation, and energy metabolism makes it an attractive target for drug development. Further research is needed to fully understand the role of clec3-alpha in this disease and to develop safe and effective treatments.

Protein Name: C-type Lectin Domain Family 3 Member A

Functions: Promotes cell adhesion to laminin-332 and fibronectin

The "CLEC3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLEC3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets